Albaconazole 100mg + Albaconazole 200mg + Albaconazole 400mg + Albaconazole 400mg + Placebo 400 mg

Phase 2Completed
0 watching 0 views this week Active
51
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Onychomycosis

Conditions

Onychomycosis

Trial Timeline

Jul 16, 2008 → Feb 19, 2010

About Albaconazole 100mg + Albaconazole 200mg + Albaconazole 400mg + Albaconazole 400mg + Placebo 400 mg

Albaconazole 100mg + Albaconazole 200mg + Albaconazole 400mg + Albaconazole 400mg + Placebo 400 mg is a phase 2 stage product being developed by GSK plc for Onychomycosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00730405. Target conditions include Onychomycosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00730405Phase 2Completed